Etaracizumab

Drug Profile

Etaracizumab

Alternative Names: Abegrin; Anti-alpha-v-beta-3 humanised monoclonal antibody; Anti-αvβ3 monoclonal antibody; LM 609; MEDI-522; Vitaxin; Vitaxin II

Latest Information Update: 21 Jun 2007

Price : $50

At a glance

  • Originator Applied Molecular Evolution; MedImmune
  • Developer Targesome
  • Class Monoclonal antibodies
  • Mechanism of Action Angiogenesis inhibitors; Apoptosis stimulants; Immunostimulants; Integrin alphaVbeta3 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • Discontinued Colorectal cancer; Malignant melanoma; Prostate cancer; Psoriasis; Rheumatoid arthritis

Most Recent Events

  • 19 Jun 2007 MedImmune has been acquired by AstraZeneca
  • 09 Mar 2007 Discontinued - Phase-II for Prostate cancer in USA (IV-infusion)
  • 09 Mar 2007 Discontinued - Phase-II for Malignant melanoma in USA (IV-infusion)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top